Darlifarnib plus cabozantinib in advanced RCC showed 33%-50% objective response rates and a median PFS of 13 months in cabozantinib-naive patients, with a manageable safety profile. The combination outperformed historical benchmarks and supports further development in both naive and TKI-exposed pop…
Darlifarnib plus cabozantinib in advanced RCC showed 33%-50% objective response rates and a median PFS of 13 months in cabozantinib-naive patients, with a manageable safety profile. The combination outperformed historical benchmarks and supports further development in both naive and TKI-exposed populations.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
